BioCentury | Nov 21, 2020
Finance

Mei readies Antengene to take its next steps to becoming a global biotech

Fresh off its $360 million IPO on the Hong Kong stock exchange, Shanghai’s Antengene is looking to take the next step in its evolution by building out its pipeline and launching its first drug....
BioCentury | Nov 18, 2020
Product Development

Nov. 17 Quick Takes: Phase III miss for BrainStorm’s ALS program; plus Novo, BioMarin-Deep Genomics, Lexicon, Seed-Lilly and RhoVac

BrainStorm sees path forward for ALS therapy despite Phase III missBrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) shed $7.92 (66%) to $4.02 on Tuesday after its mesenchymal stem cell therapy NurOwn missed the primary endpoint in a...
BioCentury | Nov 10, 2020
Finance

RemeGen’s value surpasses $4B after pricing 2020’s largest biotech IPO

After raising nearly HK$4 billion ($514.3 million) in the year’s largest biotech IPO thus far, Yantai-based RemeGen gained 34% in its first trading day, finishing Monday’s session with a valuation of $4.3 billion. The deal tops...
BioCentury | Nov 3, 2020
Finance

Nov. 3 Quick Takes: JW lists in Hong Kong; plus Fountain Healthcare’s €125M fund, and EMA reviewing GenSight, Vifor/ChemoCentryx programs

JW makes public debut on Hong Kong exchangeIn its first day of trading Tuesday, JW Therapeutics Co. Ltd. (HKEX:2126) fell HK$1.80 to HK$22 after raising HK$2.3 billion ($300 million) in an IPO. Bristol Myers Squibb...
BioCentury | Oct 28, 2020
Finance

Oct. 27 Financial Quick Takes: Apellis-Sobi deal for C3 inhibitor; plus Primmune, Prokarium, Novartis-RegenxBio, Turning Point, Psyomics, Journey Colab

Apellis, Sobi enter territorial deal for C3 inhibitorApellis Pharmaceuticals Inc. (NASDAQ:APLS) granted Swedish Orphan Biovitrum AB (SSE:SOBI) exclusive ex-U.S. rights to systemic therapy pegcetacoplan (APL-2), an inhibitor of C3. The partners will jointly develop the...
BioCentury | Oct 15, 2020
Product Development

Oct. 14 Quick Takes: FDA approves first Ebola therapy; plus Vertex tumbles after hours on AAT discontinuation

Regeneron’s Ebola mAb cocktail approvedFDA approved Inmazeb atoltivimab/maftivimab/odesivimab-ebgn from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to treat Zaire ebolavirus infection. The mAb cocktail had raised the chance of survival vs. ZMapp, a mAb combination used as a control, in...
BioCentury | Oct 10, 2020
Product Development

Oct. 9 Quick Takes: Sobi’s Phase III miss; plus Alkermes, COVAX, Warp Speed-AZ, Lilly-Gates, Pfizer, Everest and Affamed-Kissei

Sobi’s avatrombopag misses in Phase III for chemotherapy-induced thrombocytopenia Swedish Orphan Biovitrum AB (SSE:SOBI) sank 18% on Friday, shedding $1.3 billion in market cap, after CD110 agonist Doptelet avatrombopag missed the composite primary endpoint in a...
BioCentury | Oct 9, 2020
Finance

Everest balances local, international offerings in IPO that could be biggest yet on Hong Kong biotech chapter

Strong local demand allowed Everest to price what could become the largest IPO yet on the Hong Kong stock exchange’s biotech chapter with a share issue balanced between the offering’s local and international components. Cross-border...
BioCentury | Oct 8, 2020
Finance

Hillhouse’s Genor tops off busy year with IPO, plans to ‘transform’ pipeline

Genor’s $371 million IPO on the Hong Kong stock exchange’s prerevenue chapter Wednesday caps a busy 12 months for the Shanghai cancer company during which it has rebooted its C-suite, added dry powder via a...
BioCentury | Sep 30, 2020
Deals

As China’s CStone preps for launches, Pfizer buys equity stake and local rights to PD-L1 program

A deal giving Pfizer local rights to CStone’s PD-L1 inhibitor will add at least $200 million to the Suzhou-based biotech’s balance sheet as it prepares for a series of drug approvals, while taking advantage of...
Items per page:
1 - 10 of 521